More evidence is emerging to support the use of testing for circulating tumour DNA (ctDNA) as a promising way to predict whether a cancer will come back. Tumours release degraded fragments of DNA, including ctDNA, into the bloodstream. Testing a cancer patient’s blood for this DNA, using a type of blood test called a liquid […]
In the future, liquid biopsy testing is likely to play an increasing role in identifying which patients with colorectal cancer are most likely to have their cancer come back again after surgery. Liquid biopsy testing could also help doctors to decide which treatments would be most suitable to recommend to individual patients, according to new […]
We are happy to announce that we contributed to iGem Thessaloniki team’s won of the top prize in the international iGEM Synthetic Biology competition 2019, organized by MIT University in Boston. The project is called “POSEIDON” and it is a toolkit for the examination of DNA-Protein interactions. IGem team of Thessaloniki deploys the first DNA […]
Liquid biopsy tests could be an option for patients with a form of lung cancer, according to the early results of research presented at a major cancer conference. A growing number of patients with advanced lung cancer could soon be offered a blood test to help to decide the best treatment for them instead of […]
In as little as two weeks, patients and clinicians can gain access to a next-generation genetic test provided by RGCC that can analyse the sequence of both DNA and RNA. The RGCC CAMBISeq® (Cancer Analysis, Mutational Burden and Instability Sequencing) test sequences DNA and RNA – the nucleic acids that carry genomic sequence information and […]
